Cambridge, UK, 5 July 2005 -CeNeS announces that all resolutions put to Shareholders at today’s AGM were passed.
At the AGM CeNeS’ Chairman Alan Goodman said: In the last nine months CeNeS has delivered two successful clinical trial results, the first being a Phase III trial of our lead programme M6G for post-operative pain, that demonstrated its efficacy as an analgesic. The second successful result was in a Phase II proof of concept study of CNS 5161 in neuropathic pain. These results are evidence of the expertise of our clinical development team and their ability to design and implement clinical programmes. We look forward with confidence to progressing both these compounds to the next stages of their clinical development and also moving CNS 7056X, our novel short acting sedative, into the clinic in 2006.
Our earlier stage programme developing novel COMT (catechol-o-methyl transferase) inhibitors is also progressing well. The market for COMT inhibitors may expand substantially as the role of COMT is better understood in schizophrenia and other cognitive disorders in addition to the established market for the treatment of Parkinson’s disease.
I firmly believe CeNeS is well positioned to deliver value to its shareholders by further developing its balanced portfolio focused on improved treatments for disorders of the central nervous system and pain. CeNeS is looking forward with confidence to reaching important milestones in each of its programmes in the next 12 to 18 months.
For more information please contact:
CeNeS Pharmaceuticals plc
Tel: +44 (0)1223 266466
Tel: +44 (0)20 7886 8150
About CeNeS Pharmaceuticals
CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson’s disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com.
London, W1W 5BB, UK